TRIANA Biomedicines Named Most Promising New Company in BioSpace’s NextGen 2023 List
Waltham, MA – January 5, 2022 – TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on building a target-first and rational molecular glue discovery platform for inactivating difficult to address disease targets, announced today that it has been included in BioSpace’s NextGen “Class of 2023” list featuring the most promising new life sciences companies of 2023.
BioSpace, the leading source for life sciences news and careers, has been recognizing the most exciting startups in biotech and pharma for the past nine years in its NextGen list. Twenty-five companies were selected this year, spanning organizations across all therapeutic areas.
“I am excited to see TRIANA’s nomination to BioSpace’s NextGen ‘Class of 2023’. Molecular glues are a powerful modality for developing precision medicines that can transform patient lives,” said Dr. Patrick Trojer, President and CEO of TRIANA.
BioSpace’s editorial team analyzed multiple components as determining factors: finance, collaborations, pipeline, growth potential and innovation. Points were awarded for each criteria and companies ranked accordingly. This year’s list includes top-scoring organizations that launched between September 2021 and September 2022 with a Series A funding.
The complete NextGen “Class of 2023” list can be viewed on BioSpace.
About TRIANA Biomedicines Inc
TRIANA Biomedicines is a private biotechnology company, headquartered in Waltham, Massachusetts and focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art AI and computational tools, and bespoke chemical libraries. TRIANA’s target-first and rational approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
About BioSpace
BioSpace is the digital hub for life science news and jobs. BioSpace provides essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more at www.biospace.com
Contacts
Investor Relations and Media Contact
Kia Khaleghpour, PhD
Chantal Dresner
Marketing Director, BioSpace
chantal.dresner@biospace.com